Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Jul;33(4):255–262. doi: 10.1007/BF01744945

Tumor size, leukocyte adherence inhibition and serum levels of tumor antigen in dogs with the canine transmissible venereal sarcoma

Tsu-Ju Yang 1,✉, Thomas J Palker 1, Matthew W Harding 1
PMCID: PMC11038260  PMID: 2059969

Abstract

Tumor antigen (TA) associated with the canine transmissible venereal sarcoma (CTVS) was detected in the sera of dogs bearing the tumor. Rabbit antisera specific for tumor antigen and 3 M KCl extracts of CTVS cells were used in both a competitive enzyme-linked immunosorbent assay (ELISA) and antigen-capture ELISA to quantify levels of circulating TA. In a study of 29 dogs bearing the transplanted CTVS, levels of circulating TA correlated positively with tumor volume. In a longitudinal study of four dogs receiving a transplant of 108 viable CTVS cells, circulating CTVS antigen was detected transiently 2 days after transplantation, while persistent levels of TA associated with increasing tumor volume were demonstrable 19–34 days after transplantation. In three of four tumor-bearing dogs, levels of serum TA correlated inversely with values obtained with peripheral blood leukocytes in the leukocyte adherence inhibition (LAI) assay; elevated levels of circulating TA found in dogs with large (>7 cm3) tumors were associated with decreased LAI reactivity of peripheral blood leukocytes. TA could not be detected in sera 48–72 h after surgical removal of CTVS whereas LAI reactivity of peripheral blood leukocytes to CTVS antigen rebounded 1–3 weeks following tumor excision. Results of this study support the use of the competitive ELISA and LAI techniques in assessing levels of circulating tumor antigen, tumor burden and tumor-specific immunity.

Keywords: Sarcoma, Tumor Volume, Immunosorbent Assay, Tumor Burden, Tumor Antigen

Footnotes

Supported by grants from the American Kennel Club, National Institutes of Health (CA23 469) and Funds for Research on Canine Diseases provided by the 1963 Connecticut Legislature

References

  • 1.Baldwin RW, Robins RA. Factors interfering with immunological rejection of tumors. Br Med Bull. 1976;32:118–123. doi: 10.1093/oxfordjournals.bmb.a071342. [DOI] [PubMed] [Google Scholar]
  • 2.Baldwin RW, Price MR, Robins RA. Blocking of lymphocytemediated cytotoxicity for rat hepatoma cell by tumor-specific antigen-antibody complexes. Nat New Biol. 1972;238:185–187. doi: 10.1038/newbio238185a0. [DOI] [PubMed] [Google Scholar]
  • 3.Baldwin RW, Price MR, Robins RA. Inhibition of hepatomaimmune lymph-node cell cytotoxicity by tumor-bearer serum and solubilized hepatoma antigen. Int J Cancer. 1973;11:527–535. doi: 10.1002/ijc.2910110304. [DOI] [PubMed] [Google Scholar]
  • 4.Black P. Shedding from the cell surface of normal and cancer cell. Adv Cancer Res. 1980;32:75–199. doi: 10.1016/s0065-230x(08)60361-9. [DOI] [PubMed] [Google Scholar]
  • 5.Bonavida B. Studies on the induction and expression of T-cell mediated immunity. I. Blocking of cell-mediated cytolysis by membrane antigens. J Immunol. 1973;12:926–934. [PubMed] [Google Scholar]
  • 6.Bray KR, Koda JE, Gaur PK. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res. 1987;47:5853–5860. [PubMed] [Google Scholar]
  • 7.Cohen D. The biological behavior of the transmissible venereal tumor in immunosuppressed dogs. Eur J Cancer. 1973;9:253–258. doi: 10.1016/0014-2964(73)90090-x. [DOI] [PubMed] [Google Scholar]
  • 8.Cohen D. The canine transmissible venereal tumor: a unique result of tumor progression. Adv Cancer Res. 1985;43:75–112. doi: 10.1016/s0065-230x(08)60943-4. [DOI] [PubMed] [Google Scholar]
  • 9.DeMonbreun WA, Goodpasture EW. Experimental investigation concerning the nature of contagious lymphosarcoma of dogs. Am J Cancer. 1934;21:295–321. [Google Scholar]
  • 10.Grosser N, Marti JH, Proctor JW, Thomson DMP. Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Int J Cancer. 1976;18:39–47. doi: 10.1002/ijc.2910180107. [DOI] [PubMed] [Google Scholar]
  • 11.Harding MW, Yang TJ. Canine transmissible venereal sarcoma: leukocyte adherence inhibition (LAI) reactivity of various lymphoid tissues of dogs with tumors of different stages of growth. Int J Cancer. 1981;27:349–355. doi: 10.1002/ijc.2910270314. [DOI] [PubMed] [Google Scholar]
  • 12.Harding MW, Yang TJ. Sequential changes in peripheral blood leukocyte adherence inhibition (LAI) reactivity during progressive growth and spontaneous regression of canine transmissible venereal sarcoma. Int J Cancer. 1981;28:361–366. doi: 10.1002/ijc.2910280316. [DOI] [PubMed] [Google Scholar]
  • 13.Harding MW, Yang TJ. Amplification of lymph node cell leukocyte adherence inhibition (LAI) reactivity by leukocyte adherence inhibition factor (LAIF) Cell Immunol. 1984;87:206–216. doi: 10.1016/0008-8749(84)90144-8. [DOI] [PubMed] [Google Scholar]
  • 14.Harding MW, Yang TJ. Regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with progressing or spontaneously regressing canine transmissible venereal sarcoma (CTVS) Cancer Immunol Immunother. 1985;19:168–176. doi: 10.1007/BF00199222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hayes DF, Zurawski VR Jr, Kuf DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4: 1542–1550 [DOI] [PubMed]
  • 16.Hellstrom KE, Hellstrom I. Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population. Proc Natl Acad Sci USA. 1978;75:436–445. doi: 10.1073/pnas.75.1.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Herlyn M, Shen JW, Sears HF, Civin CI, Verrill HL, Goldberg EM, Koprowski H. Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants. Clin Exp Immunol. 1984;55:23–35. [PMC free article] [PubMed] [Google Scholar]
  • 18.Herlyn M, Rodeck U, Koprowski H. Shedding of human tumor associated antigens in vitro and in vivo. Adv Cancer Res. 1989;49:189–221. doi: 10.1016/s0065-230x(08)60798-8. [DOI] [PubMed] [Google Scholar]
  • 19.Kalb VF, Bernlohr RW. A new spectrophotometric assay for protein in cell extract. Anal Biochem. 1977;82:362–371. doi: 10.1016/0003-2697(77)90173-7. [DOI] [PubMed] [Google Scholar]
  • 20.Karlson AG, Mann FC. The transmissible venereal tumor of dogs: observations over forty generations of experimental transfers. Ann NY Acad Sci. 1952;54:1197–1213. doi: 10.1111/j.1749-6632.1952.tb39989.x. [DOI] [PubMed] [Google Scholar]
  • 21.Komada Y, Ochiai H, Shimizu K, Azuma E, Kamiya H, Sakurai M. Shedding of leukemia-associated P24 antigen by lymphoblastoid cell lines. J J Clin Oncol. 1987;17:333–342. [PubMed] [Google Scholar]
  • 22.Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest. 1987;79:1879–1882. doi: 10.1172/JCI113031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Leoni F, Bast RC, Jr, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer. 1987;40:592–597. doi: 10.1002/ijc.2910400503. [DOI] [PubMed] [Google Scholar]
  • 24.Lopez MJ, O'Connor R, MacFarlane JK, Thomson DMP. Abrogation of the phenomenon of leukocyte adherence inhibition by excess tumor antigen. Br J Cancer. 1978;38:660–673. doi: 10.1038/bjc.1978.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Losa GA, Heumann D, Carrel S, von Fliedner V, Mach JP. Characterization of membrane vesicles circulating in the serum of patients with common acute lymphoblastic leukemia. Lab Invest. 1986;55:573–579. [PubMed] [Google Scholar]
  • 26.Markwell MAK, Haas SM, Bieber LL, Tollbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206–210. doi: 10.1016/0003-2697(78)90586-9. [DOI] [PubMed] [Google Scholar]
  • 27.Marti JH, Grosser N, Thomson DMP. Tube leukocyte adherence inhibition for the detection of anti-tumor immunity: II. Monocyte reacts with tumor antigen via cytophilic anti-tumor antibody. Int J Cancer. 1976;18:48–57. doi: 10.1002/ijc.2910180108. [DOI] [PubMed] [Google Scholar]
  • 28.Matsunaga A, Kuroki M, Higuchi H, Arakawa F, Takakura K, Okamoto N, Matsuoka Y. Antigenic heterogeneity of carcinoembryonic antigen in the circulation defined by monoclonal antibodies against the carbohydrate moiety of carcinoembryonic antigen and closely related antigens. Cancer Res. 1987;47:56–61. [PubMed] [Google Scholar]
  • 29.Nakane PK, Kawaoi A. Peroxidase labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974;22:1084–1091. doi: 10.1177/22.12.1084. [DOI] [PubMed] [Google Scholar]
  • 30.Novinsky MA. Zentralbl Med Wiss. 1876;14:790–971. [Google Scholar]
  • 31.Palker TJ, Yang TJ. Identification and physico-chemical characterization of a tumor-associated antigen from the canine transmissible venereal sarcoma. J Natl Cancer Inst. 1981;66:779–787. [PubMed] [Google Scholar]
  • 32.Palker TJ, Yang TJ. Detection of immune complexes in sera of dogs with the canine transmissible venereal sarcoma (CTVS) by a conglutinin binding assay. J Comp Pathol. 1985;95:247–258. doi: 10.1016/0021-9975(85)90011-8. [DOI] [PubMed] [Google Scholar]
  • 33.Shenouda G, Thomson DMP. Blocking of the response by human T-lymphocytes to extracts of autologous cancer by monoclonal antibody to class I major histocompatibility gene products in the leukocyte adherence inhibition assay. Cancer Res. 1984;44:2762–2768. [PubMed] [Google Scholar]
  • 34.Slaght SS, Yang TJ, van der Heide L. Adaptation of enzymelinked immunosorbent assay to the avian system. J Clin Microbil. 1979;10:698–702. doi: 10.1128/jcm.10.5.698-702.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Swenson JJ. Physiological properties and cellular and chemical constituents of blood. In: Swenson MJ, editor. Duke's physiology of domestic animals. Ithaca, NY: Cornell University Press; 1977. p. 32. [Google Scholar]
  • 36.Thomson DMP. The LAI response to human cancer: the biology of the LAI response and features of the antigens. In: Thomson DMP, editor. Assessment of immune status by the leukocyte adherence inhibiton test. New York: Academic Press; 1982. pp. 128–166. [Google Scholar]
  • 37.Thomson DMP, Grosser N. Immunologic mechanism of tube leukocyte adherence inhibition. Cancer Res. 1979;39:576–581. [PubMed] [Google Scholar]
  • 38.Thomson DMP, Tataryn DN, Schwartz R, MacFarlane JK. The natural history of antitumor immunity in human breast cancer assayed by tube leukocyte adherance inhibition. Eur J Cancer. 1979;15:1095–1106. [Google Scholar]
  • 39.Thomson DMP, Phelon J, Morton DG, Bach MK. Armed human monocytes challenged with a sensitizing cancer extract release substances pharmacologically similar to leukotrienes. Int J Cancer. 1982;30:229–306. doi: 10.1002/ijc.2910300308. [DOI] [PubMed] [Google Scholar]
  • 40.Vennegoor C, Rumke P. Circulating melanoma-associated antigen detected by monoclonal antibody NKI/C-3. Cancer Immunol Immunother. 1986;23:93–100. doi: 10.1007/BF00199813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Yang TJ, Jones JB. Canine transmissible venereal sarcoma: transplantation studies in neonatal and adult dogs. J Natl Cancer Inst. 1973;51:1915–1918. doi: 10.1093/jnci/51.6.1915. [DOI] [PubMed] [Google Scholar]
  • 42.Yang TJ, Chandler JP, Dunne-Anway S. Growth stage-dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br J Cancer. 1987;55:131–134. doi: 10.1038/bjc.1987.27. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES